Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1967 1
1971 1
1973 2
1975 4
1976 1
1977 1
1978 1
1979 2
1980 1
1981 5
1983 4
1984 2
1985 2
1986 1
1987 4
1989 2
1990 3
1991 2
1992 7
1993 3
1994 6
1995 5
1996 10
1999 4
2000 5
2001 2
2002 6
2003 6
2004 2
2005 4
2006 2
2007 4
2008 2
2009 4
2010 5
2011 2
2012 4
2013 5
2014 2
2016 1
2017 1
2018 1
2019 7
2020 1
2021 1
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Sky-hook: old idea.
Lvov V, Issacs JD, Bradner H, Backus GE, Vine AC. Lvov V, et al. Science. 1967 Nov 17;158(3803):946-7. doi: 10.1126/science.158.3803.946. Science. 1967. PMID: 17753605 No abstract available.
Commercial articulated collaborative in situ 3D bioprinter for skin wound healing.
Levin AA, Karalkin PA, Koudan EV, Senatov FS, Parfenov VA, Lvov VA, Petrov SV, Pereira FDAS, Kovalev AV, Osidak EO, Domogatsky SP, Manturova NE, Kasyanov VA, Sergeeva NS, Zorin VL, Khesuani YD, Mironov VA. Levin AA, et al. Among authors: lvov va. Int J Bioprint. 2023 Jan 31;9(2):675. doi: 10.18063/ijb.v9i2.675. eCollection 2023. Int J Bioprint. 2023. PMID: 37065657 Free PMC article.
153 results